Patents by Inventor A. C. Morgan, Jr.
A. C. Morgan, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8528698Abstract: A container for receiving an automotive fluid includes a receptacle body defining a container volume for holding the automotive fluid. The receptacle body includes connecting structure for connecting the receptacle body to a vehicle. The receptacle body is at least partially formed by a shape changing material arranged and configured to change the container volume.Type: GrantFiled: May 5, 2010Date of Patent: September 10, 2013Assignee: Toyota Motor Engineering & Manufacturing North America, Inc.Inventor: Christopher C. Morgan, Jr.
-
Publication number: 20120064593Abstract: Superantibodies having enhanced autophilic, catalytic, and/or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and/or photoactivation. Autophilic superantibodies can promote apoptosis of target cells and/or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy. Exemplary of such diseases are atherosclerosis and cardiovascular disease.Type: ApplicationFiled: August 23, 2011Publication date: March 15, 2012Applicant: InNexus Biotechnology International Ltd.Inventors: Heinz Kohler, Sybille Muller, Alton C. Morgan, JR.
-
Publication number: 20120052515Abstract: Compositions and methods for providing antibodies having noncovalent, self-binding properties are disclosed. Such autophilic antibodies can bind cellular receptors to promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with debilitating or life-threatening diseases. Representative diseases targeted by the autophilic antibodies are lymphomas, breast cancers, colon cancers, and melanomas. Autoimmune disorders, Alzheimer's disease, and other neuro-degenerative conditions, as well as graft or transplant rejection, are among other treatable conditions.Type: ApplicationFiled: August 23, 2011Publication date: March 1, 2012Inventors: Heinz Kohler, Alton C. Morgan, JR.
-
Patent number: 8100789Abstract: A sheave for use in a continuously variable transmission comprises a truncated, substantially conical portion having an inner radius, an outer radius and a contact surface extending between the inner radius and the outer radius. The contact surface of the sheave may include a plurality of concentric step features such that the contact surface is graduated between the inner radius and the outer radius. Each step feature may include a rise portion and a pitch portion. The rise portion of each step feature and the pitch portion of each step feature may extend in a circumferential direction on the contact surface.Type: GrantFiled: November 25, 2008Date of Patent: January 24, 2012Assignee: Toyota Motor Engineering & Manufacturing North America, Inc.Inventor: Christopher C. Morgan, Jr.
-
Patent number: 7832206Abstract: Systems and methods of controlling automatic transmission fluid (ATF) in a vehicle include torque converter systems generally having a pump, a turbine and a stator. The stator is selectively rotated during periods of predetermined low ATF temperature, thereby causing temporarily induced inefficiencies that warm the ATF.Type: GrantFiled: March 12, 2008Date of Patent: November 16, 2010Assignee: Toyota Motor & Engineering North America, Inc.Inventor: Christopher C. Morgan, Jr.
-
Publication number: 20100130318Abstract: A sheave for use in a continuously variable transmission comprises a truncated, substantially conical portion having an inner radius, an outer radius and a contact surface extending between the inner radius and the outer radius. The contact surface of the sheave may include a plurality of concentric step features such that the contact surface is graduated between the inner radius and the outer radius. Each step feature may include a rise portion and a pitch portion. The rise portion of each step feature and the pitch portion of each step feature may extend in a circumferential direction on the contact surface.Type: ApplicationFiled: November 25, 2008Publication date: May 27, 2010Applicant: Toyota Motor Engineering & Manufacturing North America, Inc.Inventor: Christopher C. Morgan, JR.
-
Publication number: 20100017898Abstract: Compositions and methods for providing antibodies having noncovalent, self-binding properties are disclosed. Such autophilic antibodies can bind cellular receptors to promote apoptosis of target cells and enhance therapeutic efficacies in the treatment of patients with debilitating or life-threatening diseases. Representative diseases targeted by the autophilic antibodies are lymphomas, breast cancers, colon cancers, and melanomas. Autoimmune disorders, Alzheimer's disease, and other neuro-degenerative conditions, as well as graft or transplant rejection, are among other treatable conditions.Type: ApplicationFiled: September 18, 2009Publication date: January 21, 2010Inventors: Heinz Kohler, Alton C. Morgan, JR.
-
Publication number: 20090233763Abstract: Systems and methods of controlling automatic transmission fluid (ATF) in a vehicle include torque converter systems generally having a pump, a turbine and a stator.Type: ApplicationFiled: March 12, 2008Publication date: September 17, 2009Applicant: Toyota Motor Engineering & Manufacturing North America, Inc.'sInventor: Christopher C. Morgan, JR.
-
Publication number: 20090208418Abstract: Superantibodies having enhanced autophilic, catalytic, and/or membrane-penetrating properties are prepared by affinity-based conjugation of a photoactivatable organic molecule to a target immunoglobulin. The photoactivatable organic molecule bears a chromophoric aromatic hydrocarbon moiety, which has affinity for the immunoglobulin. Upon photolysis, the organic molecule is covalently linked to the immunoglobulin. A preferred organic molecule is a peptide and a preferred aromatic hydrocarbon moiety is a tryptophan residue. The photoactivatable organic molecule need not bear a purine, pyrimidine or azido group to effect binding to the immunoglobulin and/or photoactivation. The superantibodies can enhance the potency and expand the targeting range of target antibodies. Autophilic superantibodies can promote apoptosis of target cells and/or enhance therapeutic efficacies in the treatment of patients with diseases or disorders responsive to antibody therapy.Type: ApplicationFiled: April 29, 2005Publication date: August 20, 2009Applicant: InNexus Biotechnology Internaltional Ltd.Inventors: Heinz Kohler, Sybille Muller, Alton C. Morgan Jr.
-
Patent number: 7059169Abstract: A test apparatus for measuring the air entrainment characteristics of a fluid includes a reservoir for containing the fluid, an aerator apparatus to cause air entrainment of the fluid, and a density meter to measure the effects of air entrainment on fluid density. The test apparatus enables in-situ measurement of the transient air entrainment behavior of the fluid. A corresponding method is provided.Type: GrantFiled: February 11, 2004Date of Patent: June 13, 2006Assignee: General Motors CorporationInventors: Jill M. Cummings, Christopher C. Morgan, Jr., Roy Fewkes, James L. Linden, Diana Foghel
-
Patent number: 6304851Abstract: Systems, methods and computer program products are configured for conducting time and motion studies using a portable computing device having a memory, wherein the internal clock of the portable computing device measures the elapsed time for an observed activity as a user (i.e., time and motion study analyst) identifies the observed activity and any associated parameters, counts, measurements or comments via one or more customized user interfaces displayed on the portable computing device screen. The customized user interfaces are generated from data tables created during setup. The elapsed time, activity name, and the associated parameters, counts and comments are recorded in the memory of the portable computing device as an activity record for subsequent analysis.Type: GrantFiled: March 13, 1998Date of Patent: October 16, 2001Assignee: The Coca-Cola CompanyInventors: Kenneth C. Kmack, Kevin K. Krigline, Vicente E. Vallejo, Jackie L. Tipsword, William C. Morgan, Jr.
-
Patent number: 5635180Abstract: There is disclosed charge-modified conjugates comprising a targeting protein bound to a therapeutic or diagnostic agent. Charge-modifying a conjugate to cause an acidic shift in the isoelectric point results in prolonged serum half-life upon in vivo administration and is useful to accumulate a therapeutic agent at the target site. Conversely, charge-modification to cause a basic shift in the isoelectric point of the conjugate reduces serum half-life upon in vivo use for diagnostic imaging purposes and results in higher target-to-background ratios.Type: GrantFiled: September 26, 1995Date of Patent: June 3, 1997Assignee: NeoRx CorporationInventors: Alton C. Morgan, Jr., Gowsala P. Sivam, Paul G. Abrams
-
Patent number: 5420105Abstract: Polymeric carriers are polypeptides comprising at least one drug-binding domain that non-covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired target cells to form immunoconjugates that deliver a drug to the target cells in vivo. A polymeric carrier may be attached to a proteinaceous or a non-proteinaceous ligand or anti-ligand to form a conjugate useful in pretargeting protocols to deliver a drug to target cells in vivo. The carriers are derived from drug-binding proteins and produced through peptide synthesis or recombinant DNA technology.Type: GrantFiled: July 26, 1993Date of Patent: May 30, 1995Inventors: Linda M. Gustavson, David C. Anderson, Alton C. Morgan, Jr.
-
Patent number: 5322678Abstract: There is disclosed charge-modified conjugates comprising a targeting protein bound to a therapeutic or diagnostic agent. Charge-modifying a conjugate to cause an acidic shift in the isoelectric point results in prolonged serum half-life upon in vivo administration and is useful to accumulate a therapeutic agent at the target site. Conversely, charge-modification to cause a basic shift in the isoelectric point of the conjugate reduces serum half-life upon in vivo use for diagnostic imaging purposes and results in higher target-to-background ratios.Type: GrantFiled: February 17, 1988Date of Patent: June 21, 1994Assignee: NeoRx CorporationInventors: Alton C. Morgan, Jr., Gowsala P. Sivam, Paul G. Abrams
-
Patent number: 5252713Abstract: Polymeric carriers are polypeptides comprising at least one drug-binding domain that non-covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired target cells to form immunoconjugates that deliver a drug to the target cells in vivo. The carriers are derived from drug-binding proteins and produced through peptide synthesis or recombinant DNA technology.Type: GrantFiled: September 23, 1988Date of Patent: October 12, 1993Assignee: NeoRx CorporationInventors: Alton C. Morgan, Jr., David C. Anderson
-
Patent number: 5135736Abstract: Covalently-linked complexes (CLCs) for targeting a defined population of cells, comprising a targeting protein or peptide; a cytotoxic agent; and an enhancing moiety, wherein the enhancing moiety is capable of promoting CLC-membrane interaction are disclosed. Methods for using the claimed CLCs to obtain enhanced in vivo cytotoxicity and enhanced in vivo imaging are also described.Type: GrantFiled: August 15, 1988Date of Patent: August 4, 1992Assignee: NeoRx CorporationInventors: David C. Anderson, A. C. Morgan, Jr., Paul G. Abrams
-
Patent number: 5106951Abstract: There is disclosed an antibody and antibody-drug conjugate for targeting drug delivery as well as a class of chemicals, termed a drug-binding molecule of complementary structure (csDBM). The csDBM is designed to "fit" the drug by combining multiple non-covalent interactions between functional groups on the drug and opposing functional groups on the csDBM. The net result on the antibody-csDBM-drug conjugate is a drug stably bound to the csDBM so as not to dissociate during in vivo administration, but not so tightly bound to allow drug dissociation from the conjugate without significant loss of activity and retaining the drug's ability to bind to a higher affinity site on or within the target cell.Type: GrantFiled: March 31, 1989Date of Patent: April 21, 1992Assignee: NeoRx CorporationInventors: Alton C. Morgan, Jr., Ananthachari Srinivasan, John M. Reno, Alan R. Fritzberg, David C. Anderson
-
Patent number: 5034223Abstract: Methods for improved targeting of antibody, antibody fragments, peptides hormones, steroid hormones and conjugates thereof are disclosed. Enhanced delivery to target cells of antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, specific for a population of cells of a mammal comprises steps of administering to said mammal an adequate dosage of blocking antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, and administering to said mammal an effective dosage of said antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, specific for said population of cells. In the preferred embodiment, the specific antibodies are monoclonal antibodies directed toward tumor-associated antigen in man.Type: GrantFiled: October 9, 1987Date of Patent: July 23, 1991Assignee: NeoRx CorporationInventors: Paul G. Abrams, Robert W. Schroff, Alton C. Morgan, Jr.
-
Patent number: 4879225Abstract: A method for enhancing production of antibodies through immunization with insolubilized immune complexes is disclosed. Purified antigen or heterogeneous antigen mixtures may be combined with polyclonal or monoclonal antibody and the resultant complex bound to insolubilized protein A to form insolubilized immune complexes. Methods for improving the immunogenicity of a soluble antigen and for producing monoclonal anti-idiotypic antibodies are also disclosed. Monoclonal antibodies that are specific for a distinct, as yet unrecognized epitope may be produced by another disclosed method. Insolubilized immune complexes, comprising antigen and antibody that is either directly linked to Sepharose.RTM. or absorbed onto insolubolized protein A, and immunosorbents, comprising antibody absorbed onto insolubilized protein A, are also disclosed.Type: GrantFiled: March 11, 1987Date of Patent: November 7, 1989Assignee: NeoRx CorporationInventors: Alton C. Morgan, Jr., Clive S. Woodhouse, Robert F. McIntyre
-
Patent number: RE38008Abstract: Methods for improved targeting of antibody, antibody fragments, peptides hormones, steroid hormones and conjugates thereof are disclosed. Enhanced delivery to target cells of antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, specific for a population of cells of a mammal comprises steps of administering to said mammal an adequate dosage of blocking antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, and administering to said mammal an effective dosage of said antibodies or fragments thereof or other receptor-mediated delivery system, such as peptide, specific for said population of cells. In the preferred embodiment, the specific antibodies are monoclonal antibodies directed toward tumor-associated antigen in man.Type: GrantFiled: November 29, 2001Date of Patent: February 25, 2003Assignee: NeoRx CorporationInventors: Paul G. Abrams, Robert W. Schroff, Alton C. Morgan, Jr.